MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders.

MBX Biosciences’ (NYSE:MBX – Get Free Report) lock-up period is set to end on Wednesday, March 12th. MBX Biosciences had issued 10,200,000 shares in its IPO on September 13th. The total size of the ...

CARMEL, Ind., March 05, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...